source
- Tango and Revolution report high response rates in early pancreatic cancer combo trialTango Therapeutics and Revolution Medicines tested a combination of Tango's drug vopimetostat with Revolution's daraxonrasib in an early-stage clinical trial for pancreatic cancer. The study enroll…
- Takeda braces for $2.5 billion charge after losing Amitiza antitrust case, plans appealTakeda Pharmaceutical has revised its financial outlook to include a potential $2.5 billion charge stemming from a recent antitrust lawsuit loss involving its laxative product Amitiza. The US Dist…